Skip to main content

Table 2 Clinicopathological characteristics of the worst group (n = 67, 45.9 %), expected group (n = 52 35.6 %), and best group (n = 27, 18.5 %), according to their overall survival

From: A retrospective study of predictive factors for unexpectedly prolonged or shortened progression-free survival and overall survival among patients with metastatic renal cell carcinoma who received first-line targeted therapy

Variables (N, %)

Worst Group (<1 y)

Control Group (1–3 y)

Best Group (>3 y)

p-value

Age (years)

60.5 ± 10.7

57.1 ± 11.5

56.3 ± 10.3

0.136

Gender (Male/Female)

50/17 (74.6/25.4)

45/7 (86.5/13.5)

22/5 (81.5/18.5)

0.266

Body mass index (kg/m2)

22.9 ± 2.8

23.7 ± 2.5

24.3 ± 2.9

0.096

MSKCC criteria

59 (88.1)

43 (100)

19 (73.1)

<0.001

 Favorable risk

0

4 (9.3)

10 (52.6)

 

 Intermediate risk

39 (66.1)

34 (79.1)

9 (47.4)

 

 Poor risk

20(33.9)

5 (11.6)

0

 

Heng criteria

64 (95.5)

44 (84.6)

22 (81.5)

<0.001

 Favorable risk

2 (3.1)

9(20.5)

11 (50.0)

 

 Intermediate risk

46 (71.9)

32 (72.7)

11 (50.0)

 

 Poor risk

16 (25.0)

3 (6.8)

0

 

ECOG 0

61(93.8)

47 (100)

23(100)

0.109

1

4 (6.2)

0

0

 

Metastatic site

    

 Lung

54 (81.8)

42(84.0

23 (88.5)

0.738

 Liver

18(27.3)

6 (12.2)

1 (4.3)

0.020

 Lymph node

33 (49.3)

17 (36.2)

8 (33.3)

0.064

 Bone

23 (34.8)

16 (34.0)

6 (25.0)

0.612

 Brain

9 (13.6)

5 (10.6)

2 (8.3)

0.758

 Other metastasis

18 (27.3)

5 (10.6)

4 (16.7)

0.083

Nephrectomy

Embolization

23(34.3)

4 (5.9)

32 (61.5)

1 (1.9)

24 (88.9)

3(11.1)

<0.0010.146

Clinical T stage

43 (64.2)

35 (67.3)

 

0.179

 T1

4 (10.8)

6 (17.2)

3 (18.8)

 

 T2

3 (8.1)

8(20.0)

7 (12.5)

 

 T3

15 (40.5)

11 (31.5)

9 (31.3)

 

 T4

8 (21.6)

3 (8.6)

0 (18.8)

 

 Tx

7 (18.9)

7 (20.0)

2(18.8)

 

 N1

13 (31.0)

6 (14.6)

5 (29.4)

0.229

Synchronous metastasis

58(87.9)

31 (60.8)

8 (30.8)

0.001

Fuhrman nuclear grade

41 (61.2)

39 (75.0)

22 (81.5)

0.460

 1–2

13 (31.7)

12 (30.8)

10 (45.5)

 3–5

28 (68.3)

27 (69.2)

12 (54.5)

Histology

63 (94.0)

50 (96.2)

26 (96.3)

0.581

 Clear cell type

50 (79.4)

44 (89.8)

17 (70.8)

 Non-clear cell type

2 (3.2)

1 (2.0)

0

 Chromophobe with clear cell

2 (3.0)

2 (3.8)

2 (7.4)

 Papillary with clear cell

7 (6.5)

1 (2.3)

3 (5.1)

 Unknown type

2 (3.2)

1 (2.0)

2 (8.3)

Sarcomatoid presence

3 (4.8

1 (2.0)

2(8.3)

0.168

 Treatment

   

0.430

 Sunitinib

42 (62.7)

37 (71.2)

22(81.5)

 

 Sorafenib

9 (13.4)

6 (11.5)

2 (7.4)

 

 Pazopanib

13 (19.4)

9 (17.3)

3 (11.1)

 

 Temsirolimus

3 (4.5)

0

0

 

RECIST response

   

<0.001

 CR

0

4 (9.1)

3 (15.0)

 

 PR

9 (20.0)

19 (43.2)

9 (45.0)

 

 SD

11 (24.4)

14 (31.8)

8 (40.0)

 

 PD

25 (55.6)

7 (15.9)

0

 

Laboratory findings

    

 Leukocytosis/Leucopenia

19/1 (28.4/1.6)

4/2 (8.9/4.4)

2/1(7.4/3.7)

0.030

 Anemia

51 (76.4)

17 (37.8)

8 (29.6)

<0.001

 Thrombocytosis/penia

14/2(20.9/3.0)

4/2 (8.9/4.4)

0/0

0.041

 Neutrophilia/penia

18/0 (26.9/0)

2/1 (4.4/2.2)

2/1(7.4/3.7)

0.002

 Lymphocytosis/penia

1/37 (1.5/55.2)

4/4 (8.9/8.9)

3/1 (11.1/3.7)

<0.001

 Hyper/hypocalcemia

5/11 (7.4/16.4)

1/2 (2.2/4.4)

0/1 (0/3.7)

0.077

 Hypoalbuminemia

12(17.9)

0

0

0.002

 LDH elevated

10 (14.9)

2(4.4)

0

0.051

 Neutrophil percent high/low

16/1 (23.9/1.5)

0/8(0/17.8)

1/6 (3.7/22.2)

<0.001

PFS (mo.)

2.7 (1–9.3)

9.5 (1–28.3)

12.2 (1–68.4)

<0.001

OS (mo.)

5.5 (0.3–11.6)

21.6 (12.1–35.7)

63.1 (36.6–88.4)

<0.001